Hadassah

Hadassah Researchers Develop Definitive Biomarker for Cardiac Muscle Death and Link it to Death from Sepsis

Thursday, Jun 7 2018

Hadassah Medical Organization researchers, in collaboration with colleagues at the Hadassah-Hebrew University School of Medicine, have developed a blood test which definitively detects death of cardiac muscle cells following an acute heart attack and in the case of sepsis.

The new blood test uses methylation patterns within cell-free DNA circulating in the patient’s blood stream (cfDNA) to determine the extent of heart damage. Therefore, the researchers propose that cardiac cfDNA measurements can become a new specific marker for myocardial damage, potentially complementing currently available markers.

The plasma of healthy individuals contains essentially no cfDNA, whereas patients who have experienced an acute heart attack show a robust cardiac cfDNA signal that correlates with levels of troponin.Most interestingly, it was found that the presence of cardiac DNA in the plasma of patients with sepsis predicts a four times higher chance of these patients dying within 90 days of hospitalization. These findings, the authors say, indicate that myocardial cell death is an important determinant of mortality following sepsis, and that elevated cardiac cfDNA is a strong prognostic biomarker in sepsis. By the same token, the authors note, “the strong correlation between cardiac cfDNA and mortality underscores the importance of cardiac health in facilitating survival from sepsis. These findings may have implications for the management of septic patients.”

Although troponin, a protein biomarker, is the gold standard for diagnosing cardiac muscle damage, it does have limitations. As the researchers explain, it is difficult to determine if release of troponin into the bloodstream necessarily reflects death of cardiac muscle or just reversible cardiac muscle injury. In addition, renal dysfunction, a common condition in patients with heart disease, slows down clearance of troponin and complicates the interpretation of elevated troponin. In contrast, cardiac cfDNA directly reflects cardiac damage and is not altered by kidney dysfunction.

The researchers acknowledge that additional experiments are needed to test the idea that cardiac cfDNA is an exclusive marker of cardiomyocyte death, and to validate the clinical utility of this new biomarker.

The authors conclude that measurements of cardiac cfDNA capture cardiomyocyte (cardiac muscle) death associated with myocardial infarction, and that the cardiac cfDNA assay can identify myocardial cell death early after ischemia (insufficient blood flow) ensues. Additional more detailed clinical studies are required to determine how cardiac cfDNA compares to troponin in predicting infarct size and long-term cardiac function.

The study results were published in the April 24, 2018 online issue of Nature Communications in an article entitled “Non-invasive Detection of Human Cardiomyocyte Death Using Methylation Patterns of Circulating DNA.” The study was a collaboration among researchers from the Hadassah Medical Organization’s Department of Cardiology, Department of Cardiothoracic Surgery, Endocrinology and Metabolism Service, Department of Anesthesiology and Critical Care Medicine, and the Department of Developmental Biology and Cancer Research at The Institute for Medical Research Israel-Canada of the Hadassah-Hebrew University School of Medicine.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

Tuesday, Jun 12 2018

Hadassah Ophthalmology Department Research Highlighted by JAMA

Thanking the Hadassah Medical Organization’s researchers for their ”excellent submission” to JAMA Ophthalmology regarding a multi-center international study of the variable effectiveness of treatment for neovascular age-related macular degeneration (nAMD), the editors explained that their article was one of just a few from 12 JAMA on-line journals to be highlighted in The JAMA Network Reader this weekend.

READ MORE ›
alt_text

Monday, Jun 11 2018

Ruth Radiano: Passionate New Director of Nursing at Hadassah Hospital Mount Scopus

Translating her passion and professionalism into action, Ruth Radiano, the new Director of Nursing at Hadassah Hospital Mount Scopus, brings a background of 26 years of nursing at Hadassah.

READ MORE ›
alt_text

Thursday, Jun 7 2018

Former NYC Mayor Giuliani Calls Hadassah Hospital a Blessing

Former New York City Mayor Rudy Giuliani and his partner Dr. Maria Ryan, CEO of Cottage Hospital in Woodsville, New Hampshire visited Hadassah Medical Organization in Jerusalem today to get an update on Hadassah’s management of terror events.

READ MORE ›
alt_text

Thursday, May 31 2018

Julie Benbenishty: Bridging the Geographical Divide in Nursing Care

Julie Benbenishty, Nurse Coordinator of the Hadassah Medical Organization’s Trauma Unit, was concerned about continuity of care when her patients from the West Bank and Gaza left Hadassah. “The minute they returned home,” she relates, “I had no one to be in touch with about follow-up care.”

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More